Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Mochizuki

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Journal of Gastroenterology|January 29, 2013
Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstructionYousuke Nakai, Hiroyuki Isayama, Tsuyoshi Mukai, et al.
Hepato-Gastroenterology|April 14, 2012
Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenibYuya Tsukui, Hitoshi Mochizuki, Yuji Hoshino, et al.
Scientific Reports|September 4, 2021
Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patientsMamoru Tokunaga, Kenichiro Okimoto, Naoki Akizue, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Cancer Science|January 5, 2023
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in JapanHidenori Kage, Aya Shinozaki-Ushiku, Kazunaga Ishigaki, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
Brain Stimulation|July 17, 2010
Consensus paper: combining transcranial stimulation with neuroimagingHartwig R Siebner, Til O Bergmann, Sven Bestmann, et al.
Nature Communications|May 29, 2014
Klebsormidium flaccidum genome reveals primary factors for plant terrestrial adaptationKoichi Hori, Fumito Maruyama, Takatomo Fujisawa, et al.
Hepatology International|February 4, 2026
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across AsiaYasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Journal of Gastroenterology|January 29, 2013
Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstructionYousuke Nakai, Hiroyuki Isayama, Tsuyoshi Mukai, et al.
Hepato-Gastroenterology|April 14, 2012
Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenibYuya Tsukui, Hitoshi Mochizuki, Yuji Hoshino, et al.
Scientific Reports|September 4, 2021
Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patientsMamoru Tokunaga, Kenichiro Okimoto, Naoki Akizue, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Cancer Science|January 5, 2023
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in JapanHidenori Kage, Aya Shinozaki-Ushiku, Kazunaga Ishigaki, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
Brain Stimulation|July 17, 2010
Consensus paper: combining transcranial stimulation with neuroimagingHartwig R Siebner, Til O Bergmann, Sven Bestmann, et al.
Nature Communications|May 29, 2014
Klebsormidium flaccidum genome reveals primary factors for plant terrestrial adaptationKoichi Hori, Fumito Maruyama, Takatomo Fujisawa, et al.
Hepatology International|February 4, 2026
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across AsiaYasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, et al.
Pageof 18